West Pharmaceutical Services Gestion
Gestion contrôle des critères 4/4
Le PDG West Pharmaceutical Services est Eric Green, nommé en Apr2015, a un mandat de 11.17 ans. La rémunération annuelle totale est $ 7.19M, composée du salaire de 16.4% et des bonus 83.6%, y compris les actions et options de la société. détient directement 0.25% des actions de la société, d'une valeur de $ 62.97M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 2.4 ans et 9.8 ans.
Informations clés
Eric Green
Directeur général
US$7.2m
Rémunération totale
| Pourcentage du salaire du PDG | 16.37% |
| Durée du mandat du directeur général | 11.2yrs |
| Propriété du PDG | 0.3% |
| Durée moyenne d'occupation des postes de direction | 2.4yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 9.8yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Jun 22
WST: Injectable Exposure And High Value Mix Will Shape Balanced Future Returns
Analysts have lifted their implied price target for West Pharmaceutical Services by about $6 to reflect updated fair value assumptions and ongoing confidence in injectable exposure, high value product momentum, and management execution highlighted in recent research. Analyst Commentary Recent research on West Pharmaceutical Services centers on how well the company is positioned in injectable markets and high value product categories, and how that ties into fair value and execution risk.Mise à jour du récit • Jun 06
WST: Injectable Platforms And High Value Mix Will Support Future Earnings Power
Analysts have nudged their fair value estimate for West Pharmaceutical Services higher to about $352 per share, citing refreshed price targets around $325 to $375 and continued confidence in injectable driven growth and execution. Analyst Commentary Recent Street research has focused on how West Pharmaceutical Services is executing on growth in injectables and high value product categories, and what that could mean for valuation as price targets shift higher.Seeking Alpha • Apr 30
West Pharmaceutical: Multiple Growth Drivers Are A Tailwind
Summary West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength. I rate WST a long-term 'hold' due to exemplary dividend safety and a fortress balance sheet, but the current valuation is only slightly below fair value. Read the full article on Seeking AlphaMise à jour du récit • Apr 27
WST: Higher Margin Mix And Contract Services Expansion Will Support Earnings Power
Analysts have lifted the implied fair value estimate for West Pharmaceutical Services by about $11 to roughly $350, as a series of recent price target changes reflect updated assumptions around growth, margins and P/E multiples. Analyst Commentary Recent Street research on West Pharmaceutical Services shows a mix of upbeat and cautious messages as analysts recalibrate their models and price targets around updated assumptions for growth, margins and P/E multiples.Mise à jour du récit • Feb 07
WST: Margin Resilience And Drug Delivery Portfolio Shift Will Support Earnings Power
Analysts have trimmed their price target on West Pharmaceutical Services by about US$7. This reflects updated assumptions around slightly softer revenue growth, a modestly higher discount rate, a small adjustment to future P/E expectations, and a marginally stronger profit margin outlook.Mise à jour du récit • Jan 24
WST: 2026 Drug Delivery Focus And New Syringe Platform Will Support Earnings Power
Analysts have kept their fair value estimate for West Pharmaceutical Services steady at about $345.71 per share, with only slight tweaks to assumptions like the discount rate, long term revenue growth, profit margin, and future P/E, which together feed into their updated price target narrative. What's in the News West Pharmaceutical Services agreed to sell all manufacturing and supply rights for its SmartDose 3.5 mL On Body Delivery System, along with associated facilities, to AbbVie for total consideration of US$112.5 million at close, subject to working capital and other adjustments (Key Developments).Mise à jour du récit • Jan 07
WST: Normalizing Markets And 2026 Visibility Will Support Earnings Power
Narrative update The updated analyst price target for West Pharmaceutical Services reflects a largely steady fair value near US$346. Analysts point to recent target hikes, higher EPS estimates and a constructive view on growth drivers into 2026 as key supports for the current valuation framework.Mise à jour du récit • Dec 19
WST: Normalizing End Markets Will Support Stronger Earnings Base Into 2026
Analysts have modestly raised their price target on West Pharmaceutical Services to approximately $370, up from about $310. This reflects increased earnings estimates, a stronger setup into 2026, and improving, more stable end markets.Mise à jour du récit • Dec 05
WST: Normalizing End Markets Will Support Strong Earnings Base Into 2026
Analysts have nudged their price target for West Pharmaceutical Services slightly higher to approximately $370, reflecting increased confidence in the company’s earnings power and growth drivers as market conditions normalize and set up favorably into 2026. Analyst Commentary Analyst views on West Pharmaceutical Services remain broadly constructive, with recent target hikes reflecting growing conviction that the company can sustain its earnings recovery as end markets normalize into 2026.Mise à jour du récit • Nov 21
WST: Strong 2025 Outlook and Management Confidence Will Sustain Positive Momentum
West Pharmaceutical Services has seen its average analyst price target raised, with significant increases attributed to strong quarterly results, growing end market confidence, and a positive management outlook for 2026, according to analysts. Analyst Commentary Analysts have responded to West Pharmaceutical Services' recent performance and outlook with a range of observations tying directly to the company's valuation, execution, and growth prospects.Mise à jour du récit • Nov 07
WST: Sustained Earnings Momentum Will Drive Confidence Into 2026
West Pharmaceutical Services has seen its average analyst price target rise from approximately $321 to $351. Analysts cite continued growth drivers and improved market conditions following a strong quarterly performance.Mise à jour du récit • Oct 23
Analysts Raise Target for West Pharmaceutical Services Amid Strong Outlook and Upgraded Guidance
Analysts have increased their price target for West Pharmaceutical Services by $5 to $321. They cited the company's encouraging earnings call, management's confidence in future estimates, and stable end markets with improving investment sentiment.Article d’analyse • Jul 25
West Pharmaceutical Services, Inc.'s (NYSE:WST) Shares Climb 25% But Its Business Is Yet to Catch Up
West Pharmaceutical Services, Inc. ( NYSE:WST ) shareholders have had their patience rewarded with a 25% share price...Article d’analyse • Jul 13
Here's Why West Pharmaceutical Services (NYSE:WST) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Mar 11
West Pharmaceutical: Remains A Strong Long-Term Prospect
Summary West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's high-value products segment, driven by GLP-1 medications and biologics, is expected to boost margins and returns significantly. Despite poor timing in share buybacks and management concerns, West's valuation suggests a potential 12.8% annual return, making it a buy. Key risks include management's strategic decisions and valuation, but the worst seems behind, with attractive prices for long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
West Pharmaceuticals Takes A Plunge, But May Still Offer Opportunities
Summary The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
West Pharmaceuticals: Cannot Wrap My Head Around Valuations (Rating Downgrade)
Summary West Pharmaceutical Services stock is down 16% on deteriorating fundamentals. WST's business is contracting, with lower sales growth, compressed margins, and declining ROIC, making current valuations unjustifiable. Industry advantages exist, but high multiples and low incremental returns suggest limited compounding ability. I revise WST to hold with a $300-$330/share valuation, emphasizing the need for it to produce 4%+ sales growth and improved ROIC FY'26 to justify current prices. Read the full article on Seeking AlphaAnalyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$543m |
| Dec 31 2025 | US$7m | US$1m | US$494m |
| Sep 30 2025 | n/a | n/a | US$492m |
| Jun 30 2025 | n/a | n/a | US$488m |
| Mar 31 2025 | n/a | n/a | US$467m |
| Dec 31 2024 | US$8m | US$1m | US$493m |
| Sep 30 2024 | n/a | n/a | US$500m |
| Jun 30 2024 | n/a | n/a | US$525m |
| Mar 31 2024 | n/a | n/a | US$569m |
| Dec 31 2023 | US$9m | US$1m | US$593m |
| Sep 30 2023 | n/a | n/a | US$559m |
| Jun 30 2023 | n/a | n/a | US$519m |
| Mar 31 2023 | n/a | n/a | US$552m |
| Dec 31 2022 | US$8m | US$1m | US$586m |
| Sep 30 2022 | n/a | n/a | US$631m |
| Jun 30 2022 | n/a | n/a | US$686m |
| Mar 31 2022 | n/a | n/a | US$684m |
| Dec 31 2021 | US$9m | US$1m | US$662m |
| Sep 30 2021 | n/a | n/a | US$613m |
| Jun 30 2021 | n/a | n/a | US$519m |
| Mar 31 2021 | n/a | n/a | US$423m |
| Dec 31 2020 | US$8m | US$989k | US$346m |
| Sep 30 2020 | n/a | n/a | US$312m |
| Jun 30 2020 | n/a | n/a | US$286m |
| Mar 31 2020 | n/a | n/a | US$261m |
| Dec 31 2019 | US$7m | US$936k | US$242m |
Rémunération vs marché: La rémunération totale de Eric ($USD 7.19M ) est inférieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 14.43M ).
Rémunération et revenus: La rémunération de Eric a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Eric Green (56 yo)
11.2yrs
Titularisation
US$7,190,876
Compensation
Mr. Eric M. Green serves as Independent Director at Ecolab Inc. since December 08, 2022. He has been the Chief Executive Officer of West Pharmaceutical Services, Inc. since April 24, 2015 and its President...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 11.2yrs | US$7.19m | 0.25% $ 63.0m | |
| Senior VP & CFO | less than a year | US$11.80m | 0.0042% $ 1.0m | |
| Chief HR Officer & Senior VP | 10.7yrs | US$1.39m | 0.024% $ 5.9m | |
| SVP & Chief Proprietary Segment Officer | 1.1yrs | US$2.40m | 0.00087% $ 215.6k | |
| VP of Finance & Chief Accounting Officer | 6.1yrs | pas de données | 0.0022% $ 535.4k | |
| Senior VP & CTO | less than a year | pas de données | pas de données | |
| Vice President of Investor Relations | no data | pas de données | pas de données | |
| Senior VP | less than a year | pas de données | pas de données | |
| Vice President of Global Communications | no data | pas de données | pas de données | |
| Senior Vice President of Strategy & Corporate Development | 2.6yrs | pas de données | 0.00079% $ 195.8k | |
| Senior VP and Chief Quality & Regulatory Officer | 4.1yrs | pas de données | pas de données | |
| President of Contract Manufacturing | 2.2yrs | pas de données | pas de données |
2.4yrs
Durée moyenne de l'emploi
56yo
Âge moyen
Gestion expérimentée: L'équipe de direction de WST est considérée comme expérimentée (ancienneté moyenne 2.4 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Non-Independent Chair of the Board | 11.1yrs | US$7.19m | 0.25% $ 63.0m | |
| Independent Director | 12.3yrs | US$344.94k | 0.025% $ 6.1m | |
| Lead Independent Director | 6.3yrs | US$353.84k | 0.0067% $ 1.7m | |
| Independent Director | 1.5yrs | US$330.94k | 0.0022% $ 555.2k | |
| Independent Director | 15.3yrs | US$344.94k | 0.062% $ 15.3m | |
| Independent Director | 15.3yrs | US$329.94k | 0.065% $ 16.0m | |
| Independent Director | 9.8yrs | US$332.14k | 0.016% $ 3.9m | |
| Independent Director | 3.9yrs | US$329.94k | 0.0039% $ 959.2k | |
| Independent Director | 14.3yrs | US$329.94k | 0.045% $ 11.1m | |
| Independent Director | 9yrs | US$334.94k | pas de données | |
| Honorary Director | no data | pas de données | pas de données | |
| Independent Director | 4.8yrs | US$343.84k | 0.0051% $ 1.3m |
9.8yrs
Durée moyenne de l'emploi
65yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de WST sont considérés comme expérimentés (ancienneté moyenne 9.8 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/28 11:00 |
| Cours de l'action en fin de journée | 2026/06/26 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
West Pharmaceutical Services, Inc. est couverte par 26 analystes. 14 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Lawrence Marsh | Barclays |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |